{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:01:23Z","timestamp":1791576083349,"version":"4.3.4"},"reference-count":228,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115800","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T17:56:59Z","timestamp":1694282219000},"page":"115800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects"],"prefix":"10.1016","volume":"261","author":[{"given":"Jinxiao","family":"Ru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8618-9200","authenticated-orcid":false,"given":"Jifa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115800_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"Ruijter","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2023.115800_bib3","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.202000934","article-title":"Strategies to design selective histone deacetylase inhibitors","volume":"16","author":"Melesina","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115800_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14728222.2021.1860016","article-title":"Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy","volume":"25","author":"Kumar","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2023.115800_bib5","article-title":"Class I histone deacetylases (HDAC1-3) are histone lysine delactylases","volume":"8","author":"Carlos","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115800_bib6","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/cr.2017.68","article-title":"Class I histone deacetylases are major histone decrotonylases: evidence for critical and broad function of histone crotonylation in transcription","volume":"27","author":"Wei","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2023.115800_bib7","first-page":"9","article-title":"The regulatory enzymes and protein substrates for the lysine \u03b2-hydroxybutyrylation pathway","volume":"7","author":"He","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115800_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41421-023-00573-9","article-title":"HDAC1\/2\/3 are major histone desuccinylases critical for promoter desuccinylation","volume":"9","author":"Jia","year":"2023","journal-title":"Cell Discov"},{"key":"10.1016\/j.ejmech.2023.115800_bib9","doi-asserted-by":"crossref","first-page":"15254","DOI":"10.1074\/jbc.M908988199","article-title":"Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor","volume":"275","author":"Hu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib10","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1021\/acschembio.6b00396","article-title":"HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine","volume":"11","author":"Aramsangtienchai","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/acschembio.7b00942","article-title":"Histone Deacetylase 11 is a fatty-acid deacylase","volume":"13","author":"Kutil","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.chembiol.2018.04.007","article-title":"Histone deacetylase 11 is an \u03b5-N-myristoyllysine hydrolase","volume":"25","author":"Moreno","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15368","article-title":"Histone deacetylase 10 structure and molecular function as a polyamine deacetylase","volume":"8","author":"Hai","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115800_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102407","article-title":"Histone deacetylase-10 liberates spermidine to support polyamine homeostasis and tumor cell growth","volume":"298","author":"Stewart","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib15","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1074\/jbc.M109861200","article-title":"Molecular cloning and characterization of a novel histone deacetylase HDAC10","volume":"277","author":"Guardiola","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib16","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/nar\/30.5.1114","article-title":"Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain","volume":"30","author":"Tong","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2023.115800_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1074\/jbc.M108931200","article-title":"Isolation and characterization of mammalian HDAC10, a novel histone deacetylase","volume":"277","author":"Kao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114438","article-title":"New insights into the non-enzymatic function of HDAC6","volume":"161","author":"Zhu","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2023.115800_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112273","article-title":"Alternative splicing of HDAC7 regulates its interaction with 14-3-3 proteins to alter histone marks and target gene expression","volume":"42","author":"Agosto","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2023.115800_bib21","doi-asserted-by":"crossref","first-page":"35826","DOI":"10.1074\/jbc.M104935200","article-title":"Human HDAC7 histone deacetylase activity is associated with hdac3 in vivo","volume":"276","author":"Fischle","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd.2016.185","article-title":"Epigenetic drug discovery: breaking through the immune barrier","volume":"15","author":"Tough","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115800_bib22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrm2346","article-title":"The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men","volume":"9","author":"Yang","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms15368","article-title":"Histone deacetylase 10 structure and molecular function as a polyamine deacetylase","volume":"8","author":"Hai","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115800_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115384","article-title":"Role of Gi proteins in the regulation of blood pressure and vascular remodeling","volume":"208","author":"Li","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115800_bib25","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1038\/s41467-023-38771-4","article-title":"HDAC9-mediated epithelial cell cycle arrest in G2\/M contributes to kidney fibrosis in male mice","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115800_bib26","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/jpm12101672","article-title":"Clinical significance of the histone deacetylase 2 (HDAC-2) expression in human breast cancer","volume":"12","author":"Garmpis","year":"2022","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2164-7-90","article-title":"Differential expression of selected histone modifier genes in human solid cancers","volume":"7","author":"Ozdag","year":"2006","journal-title":"BMC Genom."},{"key":"10.1016\/j.ejmech.2023.115800_bib28","article-title":"Effect of histone deacetylase 8 gene deletion on breast cancer cellular mechanism in vitro and in vivo study","volume":"311","author":"Rahmani","year":"2022","journal-title":"LSci"},{"key":"10.1016\/j.ejmech.2023.115800_bib29","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2147\/OTT.S194986","article-title":"Histone deacetylase 6 is overexpressed and promotes tumor growth of colon cancer through regulation of the MAPK\/ERK signal pathway","volume":"12","author":"Zhang","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2023.115800_bib30","first-page":"1","article-title":"Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells","volume":"12","author":"Sharda","year":"2020","journal-title":"Clin. Epigentics"},{"key":"10.1016\/j.ejmech.2023.115800_bib31","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/1878-0261.12505","article-title":"Increased expression of the HDAC 9 gene is associated with antiestrogen resistance of breast cancers","volume":"13","author":"Linares","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2023.115800_bib32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41419-022-04751-7","article-title":"Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression","volume":"13","author":"Hanisch","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2023.115800_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/path.6007","article-title":"SIN3\u2010HDAC complex\u2010associated factor, a chromatin remodelling gene located in the 12p amplicon, is a potential germ cell tumour\u2010specific oncogene","volume":"258","author":"Jhuang","year":"2022","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejmech.2023.115800_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1597-y","article-title":"Targeting HDAC\/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2023.115800_bib35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/msb.2013.26","article-title":"The functional interactome landscape of the human histone deacetylase family","volume":"9","author":"Joshi","year":"2013","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102415","article-title":"p53 at the crossroads between different types of HDAC inhibitor-mediated cancer cell death","volume":"20","author":"Mrakovcic","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib37","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1128\/MCB.01662-07","article-title":"Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2","volume":"28","author":"Dai","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128797","article-title":"Comparison of three zinc binding groups for HDAC inhibitors-A potency, selectivity and enzymatic kinetics study","author":"Yue","year":"2022","journal-title":"Bioorg. Med. Chen. Lett."},{"key":"10.1016\/j.ejmech.2023.115800_bib39","article-title":"Repurposing of histone deacetylase inhibitors: a promising strategy to combat pulmonary fibrosis promoted by TGF-\u03b2 signalling in COVID-19 survivors","volume":"266","author":"Sivashanmugam","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib40","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115800_bib41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ejmech.2023.115800_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-HDAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2023.115800_bib43","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115800_bib44","first-page":"569","article-title":"Romidepsin treatment for relapsed or refractory peripheral and cutaneous T\u2010cell lymphoma: real\u2010life data from a national multicenter observational study","volume":"37","author":"Shimony","year":"2019","journal-title":"Hematol. Incol."},{"key":"10.1016\/j.ejmech.2023.115800_bib45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115800_bib46","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2174\/0929867325666181016163110","article-title":"Recent progress in histone deacetylase inhibitors as anticancer agents","volume":"27","author":"Cappellacci","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib47","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1021\/acsmedchemlett.9b00287","article-title":"Fluorinated analogues of the histone deacetylase inhibitor vorinostat (Zolinza): validation of a chiral hybrid bioisostere, BITE","volume":"10","author":"Erdeljac","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115800_bib48","doi-asserted-by":"crossref","first-page":"9186","DOI":"10.1039\/C7OB02339A","article-title":"Perfluorinated HDAC inhibitors as selective anticancer agents","volume":"15","author":"Walton","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib49","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.3390\/cancers13184700","article-title":"Vorinostat (SAHA) and breast cancer: an overview","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115800_bib50","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3390\/genes13122240","article-title":"Single-cell sequencing identifies master regulators affected by panobinostat in neuroblastoma cells","volume":"13","author":"Milazzo","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2023.115800_bib51","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s13577-022-00812-3","article-title":"Panobinostat inhibits breast cancer progression via Vps34-mediated exosomal pathway","volume":"36","author":"Wang","year":"2023","journal-title":"Hum. Cell"},{"key":"10.1016\/j.ejmech.2023.115800_bib52","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1007\/s12325-016-0413-7","article-title":"The role of panobinostat plus bortezomib and dexamethasone in treating relapsed or relapsed and refractory multiple myeloma: a european perspective","volume":"33","author":"F","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2023.115800_bib53","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115800_bib54","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/cas.14260","article-title":"Phase I study of vorinostat with gefitinib in BIM deletion polymorphism\/epidermal growth factor receptor mutation double\u2010positive lung cancer","volume":"111","author":"Takeuchi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib55","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1158\/1078-0432.CCR-19-1251","article-title":"Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a tacl pilot studydecitabine and vorinostat for relapsed ALL","volume":"26","author":"Burke","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115800_bib56","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.2174\/138161207781663064","article-title":"The pharmaceutical potential of histone deacetylase inhibitors","volume":"13","author":"Elaut","year":"2007","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2023.115800_bib57","article-title":"Pilot trial of chidamide, an oral histone deacetylase (HDAC) inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer","volume":"35","author":"Qingyuan","year":"2017","journal-title":"Jco"},{"key":"10.1016\/j.ejmech.2023.115800_bib58","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/138920107783018417","article-title":"Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell","volume":"8","author":"Bruserud","year":"2007","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.ejmech.2023.115800_bib59","article-title":"Vorinostat and belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors","volume":"206","author":"Reece","year":"2020","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejmech.2023.115800_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111523","article-title":"Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes","volume":"199","author":"Farooq","year":"2021","journal-title":"Colloids Surf., B"},{"key":"10.1016\/j.ejmech.2023.115800_bib61","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1182\/bloodadvances.2017007427","article-title":"A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma","volume":"1","author":"Chari","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmech.2023.115800_bib62","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood-2017-06-790469","article-title":"Vorinostat plus tacrolimus\/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT","volume":"130","author":"Choi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115800_bib63","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2023.115800_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112831","article-title":"Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment","volume":"208","author":"Peng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neurobiolaging.2016.03.001","article-title":"Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients","volume":"42","author":"Almeida","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ejmech.2023.115800_bib66","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13148-019-0775-1","article-title":"Phase I\/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia","volume":"11","author":"Tilburg","year":"2019","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2023.115800_bib67","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/cas.14260","article-title":"Phase I study of vorinostat with gefitinib in BIM deletion polymorphism\/epidermal growth factor receptor mutation double-positive lung cancer","volume":"111","author":"Takeuchi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106984","article-title":"Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed\/refractory acute myeloid leukemia","volume":"123","author":"Abedin","year":"2022","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2023.115800_bib69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00280-017-3494-3","article-title":"Phase I\/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors","volume":"81","author":"Chan","year":"2018","journal-title":"Cancer Che. Mo Pharm."},{"key":"10.1016\/j.ejmech.2023.115800_bib70","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1200\/JCO.2020.38.15_suppl.7556","article-title":"Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high\/very high-risk myelodysplastic syndromes","volume":"38","author":"Ehab","year":"2020","journal-title":"Jco"},{"key":"10.1016\/j.ejmech.2023.115800_bib71","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4652","article-title":"A phase II study of selective HDAC6 inhibition with KA2507 for second-line treatment of advanced biliary tract cancer (ABC-11)","volume":"38","author":"John","year":"2020","journal-title":"Jco"},{"key":"10.1016\/j.ejmech.2023.115800_bib72","doi-asserted-by":"crossref","first-page":"14174","DOI":"10.18632\/aging.103427","article-title":"LncRNA NEAT1\/miR-129\/Bcl-2 signaling axis contributes to HDAC inhibitor tolerance in nasopharyngeal cancer","volume":"12","author":"Xue","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.ejmech.2023.115800_bib73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-394387-3.00002-1","article-title":"Mechanisms of resistance to histone deacetylase inhibitors","volume":"116","author":"Lee","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115800_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/0008-5472.CAN-10-2799","article-title":"Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumorsautophagy blockade sensitizes MPNST to HDAC inhibitors","volume":"71","author":"Gonzalo","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115800_bib75","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1021\/acs.jmedchem.2c01523","article-title":"Strategies of targeting ck2 in drug discovery: challenges, opportunities, and emerging prospects","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib76","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ijc.2910550221","article-title":"Variable effects of sodium butyrate on the expression and function of the mdr-1 (P-glycoprotein) gene in colon carcinoma cell lines","volume":"55","author":"Frommel","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115800_bib77","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0026-895X(25)09793-7","article-title":"Rhodamine efflux patterns predict P-glycoprotein substrates in the national cancer institute drug","volume":"46","author":"Lee","year":"1994","journal-title":"Screen Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115800_bib78","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.sbi.2011.08.004","article-title":"Structure, mecha-nism, and inhibition of histone deacetylases and related metalloenzymes","volume":"21","author":"Lombardi","year":"2011","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib79","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3390\/ijms20123052","article-title":"Class I-histone deacetylase (HDAC) inhibition is superior to pan-HDAC inhibition in modulating cisplatin potency in high grade serous ovarian cancer cell lines","volume":"20","author":"Jan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114049","article-title":"Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics","volume":"229","author":"Cui","year":"2022","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib81","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/ijms23010369","article-title":"Synthesis, molecular docking and biological characterization of pyrazine linked 2-aminobenzamides as new class I selective histone deacetylase (HDAC) inhibitors with Anti-Leukemic activity","volume":"23","author":"Ibrahim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib82","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1021\/acs.jmedchem.3c00525","article-title":"Discovery of (S)-N-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6H)-yl)ethyl)benzamide as Potent class i selective HDAC inhibitor for oral anticancer drug candidate","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112291","article-title":"Purine\/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors","volume":"196","author":"Nepali","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib84","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejmech.2016.02.018","article-title":"Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors","volume":"112","author":"Sharma","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib85","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1021\/acs.jmedchem.0c00230","article-title":"Achiral derivatives of hydroxamate AR-42 potently inhibit class I HDAC enzymes and cancer cell proliferation","volume":"63","author":"Tng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103988","article-title":"Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents","volume":"101","author":"Anh","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib87","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/acsmedchemlett.0c00369","article-title":"Studying histone deacetylase inhibition and apoptosis induction of psammaplin a monomers with modified thiol group","volume":"12","author":"Bao","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115800_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103724","article-title":"Synthesis and biological evaluation of 6-phenylpurine linked hydroxamates as novel histone deacetylase inhibitors","volume":"98","author":"Chen","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib89","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00280-012-1940-9","article-title":"Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14 C material in advanced cancer patients","volume":"70","author":"Clive","year":"2012","journal-title":"Cancer Chemo. Th. Pharm."},{"key":"10.1016\/j.ejmech.2023.115800_bib90","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.1021\/acs.jmedchem.6b01385","article-title":"Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia","volume":"59","author":"McClure","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib91","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/acs.jmedchem.8b00136","article-title":"Class I HDAC inhibitors display different antitumor mechanism in leukemia and prostatic cancer cells depending on their p53 status","volume":"61","author":"Li","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib92","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.0c00442","article-title":"Design of hydrazide-bearing HDACIs based on panobinostat and their p53 and FLT3-ITD dependency in antileukemia activity","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib93","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","article-title":"Control of apoptosis by p53","volume":"22","author":"Fridman","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2023.115800_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114827","article-title":"Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2, 4-dione derivatives: histone deacetylases inhibitory activity and molecular docking study","volume":"244","author":"Hamdi","year":"2022","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128663","article-title":"Design, synthesis, and biological evaluation of \u03b2-carboline 1, 3, 4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects","volume":"64","author":"Tian","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115800_bib96","article-title":"Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors","volume":"227","author":"Er","year":"2022","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112677","article-title":"Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer","volume":"206","author":"Wei","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115345","article-title":"Pyrimethamine conjugated histone deacetylase inhibitors: design, synthesis and evidence for triple negative breast cancer selective cytotoxicity","volume":"28","author":"Wu","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114058","article-title":"Discovery of phthalazino (1, 2-b)-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113095","article-title":"Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors","volume":"211","author":"Alves Avelar","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib101","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/jm301254q","article-title":"Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells","volume":"56","author":"Marek","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib102","article-title":"Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells","volume":"28","author":"Yodita","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112648","article-title":"Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer","volume":"205","author":"Yao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114011","article-title":"Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy","volume":"228","author":"Turkman","year":"2022","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/acs.jmedchem.9b00924","article-title":"Old but gold: tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases","volume":"63","author":"Brindisi","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib106","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/cancers13040634","article-title":"Anticancer therapy with hdac inhibitors: mechanism-based combination strategies and future perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115800_bib107","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2023.115800_bib108","first-page":"1","article-title":"ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy","volume":"44","author":"Park","year":"2021","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2023.115800_bib109","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/MCB.01154-06","article-title":"Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally","volume":"28","author":"Zhang","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib110","article-title":"HDAC6 as privileged target in drug discovery: a perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2023.115800_bib111","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/acs.jmedchem.8b01957","article-title":"Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer","volume":"62","author":"Shouksmith","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib112","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115800_bib113","first-page":"56","article-title":"Class I\/IIb-selective HDAC inhibitor exhibits oral bioavailability and therapeutic efficacy in acute myeloid leukemia","volume":"11","author":"Andrew","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115800_bib114","article-title":"PTG-0861: a novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia","volume":"201","author":"Justyna","year":"2020","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib115","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/acs.jmedchem.0c01922","article-title":"Unique molecular interaction with the histone deacetylase 6 catalytic tunnel: crys-tallographic and biological characterization of a model chemotype","volume":"64","author":"Olaoye","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib116","first-page":"13459","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"PANS (Pest. Artic. News Summ.)"},{"key":"10.1016\/j.ejmech.2023.115800_bib117","doi-asserted-by":"crossref","first-page":"8486","DOI":"10.1021\/acs.jmedchem.1c00420","article-title":"Development of HDAC inhibitors exhibiting therapeutic potential in T-cell prolymphocytic leukemia","volume":"64","author":"Toutah","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib118","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1021\/acschemneuro.8b00600","article-title":"Brain penetrable histone deacetylase 6 inhibitor SW-100 ameliorates memory and learning impairments in a mouse model of Fragile X Syndrome","volume":"10","author":"Kozikowski","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115800_bib119","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1021\/acs.biochem.8b00367","article-title":"Entropy as a driver of selectivity for inhibitor binding to histone deacetylase 6","volume":"57","author":"Porter","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115800_bib120","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1021\/acs.jmedchem.0c02210","article-title":"Tetrahydroquinoline-capped histone deacetylase 6 inhibitor SW-101 ameliorates pathological phenotypes in a charcotemarieetooth type 2A mouse model","volume":"64","author":"Shen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113383","article-title":"Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction","volume":"218","author":"Guo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113338","article-title":"Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: a preliminary attempt to unravel the enigma of glioblastoma","volume":"217","author":"Nepali","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib123","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/npp.2013.207","article-title":"Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability","volume":"39","author":"Jochems","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2023.115800_bib124","doi-asserted-by":"crossref","first-page":"10711","DOI":"10.1021\/acs.jmedchem.9b01194","article-title":"Novel benzohydroxamate-based potent and selective histone deacetylase 6 (HDAC6) inhibitors bearing a pentaheterocyclic scaffold: design, synthesis, and biological evaluation","volume":"62","author":"Vergani","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111950","article-title":"Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: rational design, synthesis and antiproliferative activity","volume":"187","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112998","article-title":"Novel quinolone-based potent and selective HDAC6 inhibitors: synthesis, molecular modeling studies and biological investigation","volume":"212","author":"Relitti","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116085","article-title":"Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors","volume":"35","author":"Tavares","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105874","article-title":"Design, synthesis, and biological evaluation of HDAC6 inhibitors based on cap modification strategy","volume":"125","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113419","article-title":"Synthesis and biological evaluation of phenothiazine derivative-containing hydroxamic acids as potent class II histone deacetylase inhibitors","volume":"219","author":"Hsu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib130","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1021\/acs.jmedchem.9b01888","article-title":"Multicomponent synthesis, binding mode and structure-activity relationships of selective histone deacetylase 6 (HDAC6) inhibitors with bifurcated capping groups","volume":"63","author":"Re\u00dfing","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib131","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/jhet.4538","article-title":"Design, and synthesis of N-benzyl spiro-piperidine hydroxamic acid-based derivatives: histone deacetylase inhibitory activity and drug-likeness prediction","volume":"59","author":"Kurapati","year":"2022","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib132","article-title":"Discovery of HDAC6, HDAC8, and 6\/8 inhibitors and development of cell-based drug screening models for the treatment of TGF-\u03b2-induced idiopathic pulmonary fibrosis","author":"Wei","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib133","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1039\/D2CC01550A","article-title":"Identification of mercaptoacetamide-based HDAC6 inhibitors via a lean inhibitor strategy: screening, synthesis, and biological evaluation","volume":"58","author":"Geurs","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2023.115800_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112887","article-title":"A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors","volume":"209","author":"Tavares","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jscs.2022.101450","article-title":"Design, synthesis, and biological evaluation of novel histone deacetylase 6 selective inhibitors","volume":"26","author":"Zhang","year":"2022","journal-title":"J. Saudi Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115800_bib136","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/acs.jmedchem.1c01863","article-title":"Discovery of novel histone deacetylase 6 (HDAC6) inhibitors with enhanced antitumor immunity of anti-pd-l1 immunotherapy in melanoma","volume":"64","author":"Peng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib137","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1073\/pnas.92.16.7162","article-title":"Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide\/superoxide in cortical cell cultures","volume":"92","author":"Bonfoco","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115800_bib138","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1084\/jem.169.5.1543","article-title":"Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells","volume":"169","author":"Stuehr","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib139","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1021\/acs.jmedchem.5b00317","article-title":"Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor","volume":"58","author":"Duan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib140","doi-asserted-by":"crossref","first-page":"10080","DOI":"10.1021\/acs.jmedchem.3c00977","article-title":"Discovery of the first irreversible hdac6 isoform selective inhibitor with potent anti-multiple myeloma activity","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib141","doi-asserted-by":"crossref","first-page":"12140","DOI":"10.1021\/acs.jmedchem.2c00853","article-title":"First-in-class hydrazide-based HDAC6 selective inhibitor with potent oral anti-inflammatory activity by attenuating NLRP3 inflammasome activation","volume":"65","author":"Yue","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib142","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/cbdd.14055","article-title":"Synthesis and structure\u2010activity relationship of thiol\u2010based histone deacetylase 6 inhibitors","volume":"100","author":"Guo","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2023.115800_bib143","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1096\/fj.201801680R","article-title":"The unraveling of substrate specificity of histone deacetylase 6 domains using acetylome peptide microarrays and peptide libraries","volume":"33","author":"Kutil","year":"2019","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2023.115800_bib144","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1021\/acs.biochem.9b00934","article-title":"Structural basis of catalysis and inhibition of HDAC6 CD1, the enigmatic catalytic domain of histone deacetylase 6","volume":"58","author":"Osko","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115800_bib145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbagen.2019.01.001","article-title":"Covalent inhibition of histone deacetylase 8 by 3, 4-dihydro-2H-pyrimido (1, 2-c)(1, 3) benzothiazin-6-imine","volume":"1863","author":"Marius","year":"2019","journal-title":"BBA-GEN Subjects"},{"key":"10.1016\/j.ejmech.2023.115800_bib146","first-page":"11 15","article-title":"Why hydroxamates may not be the best histone deacetylase inhibitors-what some may have forgotten or would rather forget?","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115800_bib147","article-title":"Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity","volume":"138","author":"Prakruti","year":"2019","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib148","doi-asserted-by":"crossref","first-page":"8634","DOI":"10.1021\/acs.jmedchem.0c01025","article-title":"Characterization of conformationally constrained benzanilide scaffolds for potent and selective HDAC8 targeting","volume":"63","author":"Hassan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib149","article-title":"Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation","volume":"100","author":"Neha","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105050","article-title":"Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors","volume":"114","author":"Routholla","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib151","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1021\/acs.jmedchem.0c02104","article-title":"Discovery of novel plasmodium falciparum HDAC1 inhibitors with dual-stage antimalarial potency and improved safety based on the clinical anticancer drug candidate quisinostat","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib152","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acs.jmedchem.0c01967","article-title":"HDAC7 inhibition by phenacetyl and phenylbenzoyl hydroxamates","volume":"64","author":"Mak","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103988","article-title":"Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents","volume":"101","author":"Anh","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105446","article-title":"Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model","volume":"117","author":"Routholla","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib155","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1021\/acsmedchemlett.0c00462","article-title":"Discovery of highly selective and potent HDAC3 inhibitors based on a 2-substituted benzamide zinc binding group","volume":"11","author":"Liu","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115800_bib156","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/07357907.2021.1983584","article-title":"Phase II study of single-agent and combination everolimus and panobinostat in relapsed or refractory diffuse large B-cell lymphoma","volume":"39","author":"Prioty","year":"2021","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ejmech.2023.115800_bib157","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cbpa.2020.05.009","article-title":"Two-hit wonders: the expanding universe of multitargeting epigenetic agents","volume":"57","author":"De","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib158","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib159","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115800_bib160","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.jmedchem.0c00193","article-title":"Design, synthesis and biological evaluation of quinazolin-4-one based hydroxamic acids as dual PI3K\/HDAC inhibitors","volume":"63","author":"Thakur","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib161","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1021\/acs.jmedchem.9b00390","article-title":"Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117067","article-title":"Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K\/HDAC dual inhibitors","volume":"74","author":"Wang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib163","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3410\/B1-98","article-title":"BRD4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4","volume":"1","author":"Chiang","year":"2009","journal-title":"F1000 Biol Rep"},{"key":"10.1016\/j.ejmech.2023.115800_bib164","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrm3953","article-title":"Getting up to speed with transcription elongation by RNA polymerase II","volume":"16","author":"Jonkers","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molcel.2014.05.018","article-title":"Chromatin reader BRD4 functions in Ig class switching as a repair complex adaptor of nonhomologous end-joining","volume":"55","author":"Stanlie","year":"2014","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2023.115800_bib166","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1021\/acs.jmedchem.9b02178","article-title":"Discovery of thieno(2,3-d) pyrimidine-based hydroxamic acid derivatives as bromodomain-containing protein 4\/histone deacetylase dual inhibitors induce autophagic cell death incolorectal carcinoma cells","volume":"63","author":"Pan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib167","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bioorg.2018.12.011","article-title":"Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC\/BRD4 dual inhibitors and anti-leukemia agents","volume":"84","author":"Cheng","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib168","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1002\/anie.201915896","article-title":"Potent dual BET\/HDAC inhibitors for efficient treatment of pancreatic cancer","volume":"59","author":"He","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2023.115800_bib169","doi-asserted-by":"crossref","first-page":"14620","DOI":"10.1021\/acs.jmedchem.1c01119","article-title":"4-acyl pyrrole capped HDAC inhibitors: a new scaffold for hybrid inhibitors of BET proteins and histone deacetylases as antileukemia drug leads","volume":"64","author":"Linda","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112868","article-title":"Discovery of selective HDAC\/BRD4 dual inhibitors as epigenetic probes","volume":"209","author":"Chen","year":"2021","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib171","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1021\/acs.jmedchem.2c01191","article-title":"BET-HDAC dual inhibitors for combinational treatment of breast cancer and concurrent candidiasis","volume":"66","author":"Huang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib172","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jprot.2017.08.015","article-title":"Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib","volume":"170","author":"Vyse","year":"2018","journal-title":"J. Proteonomics"},{"key":"10.1016\/j.ejmech.2023.115800_bib173","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1021\/acs.jmedchem.8b00384","article-title":"Discovery of novel pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously","volume":"61","author":"Zang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib174","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10637-021-01169-4","article-title":"Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents","volume":"40","author":"Xue","year":"2021","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2023.115800_bib175","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1039\/D1MD00125F","article-title":"Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks","volume":"12","author":"Upadhyay","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib176","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2023.115800_bib177","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/acsmedchemlett.0c00014","article-title":"Design of first-in-class dual EZH2\/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells","volume":"11","author":"Romanelli","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115800_bib178","doi-asserted-by":"crossref","first-page":"12838","DOI":"10.1021\/acs.jmedchem.2c00673","article-title":"Histone deacetylase and enhancer of zeste homologue 2 dual inhibitors presenting a synergistic effect for the treatment of hematological malignancies","volume":"13","author":"Lu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib179","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.stem.2014.05.006","article-title":"Chromatin repressive complexes in stem cells, development, and cancer","volume":"14","author":"Laugesen","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejmech.2023.115800_bib180","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41467-017-02242-4","article-title":"Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors","volume":"9","author":"Kalin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115800_bib181","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.3390\/cancers14236014","article-title":"Dual LSD1 and HDAC6 inhibition induces doxorubicin sensitivity in acute myeloid leukemia cells","volume":"14","author":"Bulut","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115800_bib182","article-title":"Novel dual LSD1\/HDAC6 inhibitors for the treatment of multiple myelom","volume":"34","author":"Sadhu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115800_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116524","article-title":"Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents","volume":"53","author":"Zheng","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib184","doi-asserted-by":"crossref","first-page":"16541","DOI":"10.1021\/acs.jmedchem.2c01413","article-title":"Design and synthesis of fibroblast growth factor receptor (FGFR) and histone deacetylase (HDAC) dual inhibitors for the treatment of cancer","volume":"64","author":"Wan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib185","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/DDDT.S351049","article-title":"Design, synthesis, and biological evaluation of 2-anilino-4-triazolpyrimidine derivatives as CDK4\/HDACs inhibitors","volume":"16","author":"Wang","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2023.115800_bib186","article-title":"Pyrazolo (3, 4-d) pyrimidine-based dual HDAC\/Topo II inhibitors: design, synthesis, and biological evaluation as potential antitumor agents","author":"Dong","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2023.115800_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114582","article-title":"Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay","volume":"240","author":"Chae","year":"2022","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114634","article-title":"Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity","volume":"241","author":"Chen","year":"2022","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105702","article-title":"Design, synthesis, and structure-activity relationships of evodiamine-based topoisomerase (Top)\/histone deacetylase (HDAC) dual inhibitors","volume":"122","author":"Zhu","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib190","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jmedchem.0c02111","article-title":"Discovery of novel pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK\/HDAC dual inhibitors for the treatment of refractory solid tumors","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib191","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1021\/acs.jmedchem.1c00136","article-title":"Discovery of STAT3 and histone deacetylase (HDAC) dual-pathway inhibitors for the treatment of solid cancer","volume":"64","author":"Ren","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib192","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-molecule PROTACS: new approaches to protein degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2023.115800_bib193","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.bmcl.2018.05.057","article-title":"Development of the first small molecule histone deacetylase 6 (HDAC6) degraders","volume":"28","author":"Yang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115800_bib194","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1021\/acs.jmedchem.9b00516","article-title":"Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity","volume":"62","author":"Wu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112800","article-title":"Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)","volume":"208","author":"Cao","year":"2020","journal-title":"Eur. J. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib196","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1039\/D2CC00272H","article-title":"Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)","volume":"58","author":"Chotitumnavee","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2023.115800_bib197","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1021\/acs.jmedchem.2c00739","article-title":"Structure-based discovery of selective histone deacetylase 8 degraders with potent anticancer activity","volume":"66","author":"Huang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib198","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.3390\/ijms23147535","article-title":"Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity","volume":"23","author":"Darwish","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib199","doi-asserted-by":"crossref","first-page":"22494","DOI":"10.1002\/anie.202006725","article-title":"Hydroxamic acids immobilized on resins (HAIRs): synthesis of dual-targeting HDAC inhibitors and HDAC degraders (PROTACs)","volume":"59","author":"Sinatra","year":"2020","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib200","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1021\/acsmedchemlett.0c00046","article-title":"Development of selective histone deacetylase 6 (HDAC6) degraders recruiting von hippel-lindau (VHL) E3 ubiquitin ligase","volume":"11","author":"Yang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115800_bib201","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1039\/D0CC03243C","article-title":"Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs","volume":"56","author":"Xiao","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2023.115800_bib202","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1039\/D0CC01485K","article-title":"PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes","volume":"56","author":"Smalley","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2023.115800_bib203","doi-asserted-by":"crossref","first-page":"11087","DOI":"10.1039\/D2CC03712B","article-title":"Development of the first non-hydroxamate selective HDAC6 degraders","volume":"58","author":"Keuler","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2023.115800_bib204","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1021\/ja311795d","article-title":"Comprehensive mathematical model for three-body binding equilibria","volume":"135","author":"Douglass","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115800_bib205","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.cell.2020.10.038","article-title":"Mapping the degradable kinome provides a resource for expedited degrader development","volume":"183","author":"Donovan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115800_bib206","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1021\/acschembio.8b00705","article-title":"Modulating PCAF\/GCN5 immune cell function through a PROTAC approach","volume":"13","author":"Bassi","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib207","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.chembiol.2021.07.002","article-title":"Chemo-proteomics exploration of HDAC degradability by small molecule degraders","volume":"28","author":"Xiong","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115800_bib208","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.tips.2013.04.007","article-title":"Targeting protein-protein interactions as an anticancer strategy","volume":"34","author":"Ivanov","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib209","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.4155\/fmc.15.138","article-title":"Protein-protein interactions as drug targets","volume":"7","author":"Skwarczynska","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib210","article-title":"Recent advances in class IIa histone deacetylases research","volume":"27","author":"Yodita","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib211","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd3680","article-title":"Protein\u2013protein interaction inhibitors get into the groove","volume":"11","author":"Mullard","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115800_bib212","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1016\/j.bmcl.2013.03.034","article-title":"Inhibitors of the p53\/hdm2 protein\u2013protein interaction\u2014path to the clinic","volume":"23","author":"Carry","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115800_bib213","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2017.03.006","article-title":"Multifaceted anticancer activity of BH3 mimetics: current evidence and future prospects","volume":"136","author":"Opydo-Chanek","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115800_bib214","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115800_bib215","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.3390\/ijms20184445","article-title":"Emerging screening approaches in the development of Nrf2\u2013Keap1 protein\u2013protein interaction inhibitors","volume":"20","author":"Leung","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib218","first-page":"213","article-title":"Recent advances in the development of protein\u2013protein interactions modulators: mechanisms and clinical trials","volume":"5","author":"Lu","year":"2020","journal-title":"Int. J. Software Tool. Technol. Tran."},{"key":"10.1016\/j.ejmech.2023.115800_bib216","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pbiomolbio.2015.01.009","article-title":"Flexibility and small pockets at protein-protein interfaces: new insights into druggability","volume":"119","author":"Jubb","year":"2015","journal-title":"Pro. Bio. Phys. Mol. Bio."},{"key":"10.1016\/j.ejmech.2023.115800_bib217","first-page":"11","article-title":"Current challenges and opportunities in designing protein\u2013protein interaction targeted drugs","volume":"13","author":"Shin","year":"2020","journal-title":"Adv. App. Bio. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib219","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1039\/D1SC00023C","article-title":"Query-guided protein-protein interaction inhibitor discovery","volume":"12","author":"Sergio","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib220","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/acschemneuro.8b00729","article-title":"How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from trichostatin a enantiomers based on molecular dynamics","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115800_bib221","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/07391102.2019.1711191","article-title":"Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study","volume":"39","author":"Kashyap","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2023.115800_bib222","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1402","article-title":"Molecular dynamics simulations of macromolecular crystals","volume":"9","author":"Cerutti","year":"2019","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115800_bib223","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2023.108510","article-title":"Exploring structural requirements of HDAC10 inhibitors through comparative machine learning approaches","volume":"123","author":"Bhattacharya","year":"2023","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2023.115800_bib224","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/molecules27030715","article-title":"HDAC inhibitors: innovative strategies for their design and applications","volume":"27","author":"Da\u015bko","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115800_bib225","first-page":"156","article-title":"HDAC6 score: to treat or not to treat?","volume":"4","author":"Hey","year":"2022","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.ejmech.2023.115800_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114062","article-title":"DYRK1A inhibitors for disease therapy: current status and perspectives","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib227","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115102","article-title":"Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases","volume":"248","author":"Xin","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115800_bib228","doi-asserted-by":"crossref","first-page":"11454","DOI":"10.1021\/acs.jmedchem.2c00844","article-title":"Progress and challenges in targeted protein degradation for neurodegenerative disease therapy","volume":"65","author":"Fang","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:55:39Z","timestamp":1759330539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423007675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":228,"alternative-id":["S0223523423007675"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115800","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115800"}}